HRP20090646T1 - Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata - Google Patents
Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata Download PDFInfo
- Publication number
- HRP20090646T1 HRP20090646T1 HR20090646T HRP20090646T HRP20090646T1 HR P20090646 T1 HRP20090646 T1 HR P20090646T1 HR 20090646 T HR20090646 T HR 20090646T HR P20090646 T HRP20090646 T HR P20090646T HR P20090646 T1 HRP20090646 T1 HR P20090646T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- treatment
- mta
- prevention
- medication
- Prior art date
Links
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 title claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 6
- 230000002265 prevention Effects 0.000 title claims abstract 5
- 206010052779 Transplant rejections Diseases 0.000 title claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 9
- 229940002612 prodrug Drugs 0.000 claims abstract 3
- 239000000651 prodrug Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000001934 delay Effects 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2005/000139 WO2006097547A1 (es) | 2005-03-17 | 2005-03-17 | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
HR20090646 | 2009-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20090646T1 true HRP20090646T1 (hr) | 2010-01-31 |
Family
ID=36991307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090646T HRP20090646T1 (hr) | 2005-03-17 | 2009-12-04 | Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata |
Country Status (19)
Country | Link |
---|---|
US (1) | US7820637B2 (pl) |
EP (1) | EP1891961B1 (pl) |
JP (1) | JP2008533107A (pl) |
CN (1) | CN101141970A (pl) |
AT (1) | ATE442854T1 (pl) |
AU (1) | AU2005329287B2 (pl) |
BR (1) | BRPI0520129A2 (pl) |
CA (1) | CA2601557A1 (pl) |
CY (1) | CY1109539T1 (pl) |
DE (1) | DE602005016729D1 (pl) |
DK (1) | DK1891961T3 (pl) |
ES (1) | ES2334924T3 (pl) |
HR (1) | HRP20090646T1 (pl) |
MX (1) | MX2007011327A (pl) |
PL (1) | PL1891961T3 (pl) |
PT (1) | PT1891961E (pl) |
RS (1) | RS51122B (pl) |
SI (1) | SI1891961T1 (pl) |
WO (1) | WO2006097547A1 (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
CN102573854A (zh) * | 2009-06-11 | 2012-07-11 | 普罗耶克托生物医学Cima有限公司 | 5’-甲硫腺苷的神经保护特性 |
WO2011054990A2 (es) * | 2009-11-05 | 2011-05-12 | Proyecto De Biomedicina Cima, S.L. | Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal |
JP5801572B2 (ja) * | 2011-03-03 | 2015-10-28 | シーシーアイ株式会社 | PPARγ活性化剤 |
CN105153042B (zh) * | 2015-07-17 | 2017-11-24 | 四川大学 | 一种化合物及其在制备治疗可卡因成瘾的药物中的用途 |
WO2020206289A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
WO2020206299A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
CN114515294A (zh) | 2022-02-25 | 2022-05-20 | 浙江中医药大学 | 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1193529B (it) * | 1980-04-22 | 1988-07-08 | Bioresearch Srl | Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo |
IT1227049B (it) * | 1988-07-29 | 1991-03-14 | Bioresearch Spa | Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante. |
ATE271063T1 (de) * | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
CA2306811A1 (en) * | 1997-10-14 | 1999-04-22 | Yoshiyuki Aoki | Piperazine compounds and medicinal use thereof |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
JP2001072660A (ja) * | 1999-09-08 | 2001-03-21 | Welfide Corp | TNF−α産生抑制剤および/またはIL−10産生促進剤 |
CZ20022413A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4 |
AU2001241067A1 (en) * | 2000-03-09 | 2001-09-17 | Ono Pharmaceutical Co. Ltd. | Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient |
WO2003028712A2 (en) * | 2001-09-28 | 2003-04-10 | Universite Libre De Bruxelles | Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
DE10207843A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
IL148736A0 (en) * | 2002-03-18 | 2002-09-12 | Pharmos Corp | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
-
2005
- 2005-03-17 ES ES05728461T patent/ES2334924T3/es active Active
- 2005-03-17 RS RSP-2009/0549A patent/RS51122B/sr unknown
- 2005-03-17 MX MX2007011327A patent/MX2007011327A/es active IP Right Grant
- 2005-03-17 SI SI200530844T patent/SI1891961T1/sl unknown
- 2005-03-17 PT PT05728461T patent/PT1891961E/pt unknown
- 2005-03-17 CA CA002601557A patent/CA2601557A1/en not_active Abandoned
- 2005-03-17 EP EP05728461A patent/EP1891961B1/en active Active
- 2005-03-17 AU AU2005329287A patent/AU2005329287B2/en not_active Ceased
- 2005-03-17 DE DE602005016729T patent/DE602005016729D1/de active Active
- 2005-03-17 PL PL05728461T patent/PL1891961T3/pl unknown
- 2005-03-17 CN CNA2005800491430A patent/CN101141970A/zh active Pending
- 2005-03-17 JP JP2008501337A patent/JP2008533107A/ja not_active Ceased
- 2005-03-17 DK DK05728461T patent/DK1891961T3/da active
- 2005-03-17 US US11/908,697 patent/US7820637B2/en not_active Expired - Fee Related
- 2005-03-17 AT AT05728461T patent/ATE442854T1/de active
- 2005-03-17 WO PCT/ES2005/000139 patent/WO2006097547A1/es active Application Filing
- 2005-03-17 BR BRPI0520129-2A patent/BRPI0520129A2/pt not_active IP Right Cessation
-
2009
- 2009-12-02 CY CY20091101268T patent/CY1109539T1/el unknown
- 2009-12-04 HR HR20090646T patent/HRP20090646T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
RS51122B (sr) | 2010-10-31 |
SI1891961T1 (sl) | 2010-01-29 |
DK1891961T3 (da) | 2009-12-21 |
MX2007011327A (es) | 2008-01-28 |
US7820637B2 (en) | 2010-10-26 |
AU2005329287B2 (en) | 2011-01-27 |
EP1891961A1 (en) | 2008-02-27 |
EP1891961B1 (en) | 2009-09-16 |
DE602005016729D1 (de) | 2009-10-29 |
ES2334924T3 (es) | 2010-03-17 |
AU2005329287A1 (en) | 2006-09-21 |
PT1891961E (pt) | 2009-12-17 |
ATE442854T1 (de) | 2009-10-15 |
PL1891961T3 (pl) | 2010-02-26 |
CY1109539T1 (el) | 2014-08-13 |
US20090042831A1 (en) | 2009-02-12 |
JP2008533107A (ja) | 2008-08-21 |
CA2601557A1 (en) | 2006-09-21 |
BRPI0520129A2 (pt) | 2009-04-28 |
CN101141970A (zh) | 2008-03-12 |
WO2006097547A1 (es) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090646T1 (hr) | Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata | |
ES2659205T3 (es) | Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune | |
RU2010113964A (ru) | Применение соматостатина-14 в качестве терапевтического средства | |
RU2010114018A (ru) | Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства | |
SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
DK0911033T3 (da) | Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis | |
HRP20040752B1 (hr) | Superfina formulacija formoterola | |
WO2009039964A3 (en) | Use of glucagon-like peptide as a therapeutic agent | |
EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ | |
RU2010108222A (ru) | Связывающие sdf-1 нуклеиновые кислоты и их применение | |
WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
NO20054767L (no) | Sammensetninger omfattende apomorfin for inhalering i lunge | |
DE68901153D1 (de) | Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
Noori et al. | Effect of family-centered empowerment model on quality of life in patients with hypertension | |
WO2009040085A3 (en) | Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) | |
EA200971073A1 (ru) | Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа | |
DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
AR012723A1 (es) | Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos | |
Swart et al. | Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies | |
DK1289535T3 (da) | Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme | |
RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
de Jong et al. | Local anesthetics: Injection route alters relative toxicity of bupivacaine | |
Hejtmancik et al. | Symmetrical peripheral gangrene complicating pulmonary embolism |